Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques

Table 1 Patient characteristics and pathologic outcomes

Case	Age (yr)	BMI (kg/m2)	Maximum PSA (ng/mL)	Prostate volume	MRI	PET/CT	Bone scan	Pathology tumor stage	Gleason score	Positive lymph nodes
1	61	25.4	8.6	40	+	/	/	T3aN0	3 + 4 = 7	0
2	71	25.3	>1000	23	+	/	+	T3bN0	4 + 5 = 9	0
3	62	24.5	>1000	30	+	/	+	T2cN1	5 + 4 = 9	16/22
4	76	25.3	18.3	80	+	/	/	T2cN0	4 + 3 = 7	0
5	79	22.4	41.2	20	+	+	/	T2cN0	5 + 5 = 10	0
6	80	23.3	15.2	46	+	/	/	Benign prostatic hyperplasia		0
7	73	23.4	27.7	31	+	+	/	T3aN0	4 + 4 = 8	0
8	56	23.2	9.2	41	+	+	/	T2aN0	3 + 3 = 6	0
9	69	26.6	22	47	+	+	/	T3aN0	4 + 5 = 9	0
10	67	24.5	4.3	27	+	+	/	T2bN0	3 + 4 = 7	0
11	65	27.6	15.9	65	+	+	/	T2cN0	3+ 3 = 6	0

+: Positive. /: not receiving the test; BMI: Body mass index; PSA: Prostatic specific antigen; MRI: Magnetic resonance imaging; PET/CT: Positron emission tomography and computed tomography.